{
    "clinical_study": {
        "@rank": "151217", 
        "arm_group": {
            "arm_group_label": "Recombinant Human Endostatin", 
            "arm_group_type": "Experimental", 
            "description": "All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein  through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks."
        }, 
        "brief_summary": {
            "textblock": "Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the\n      local control of tumors, especially the squamous cell carcinomas. Preclinical models have\n      shown that Endostar may transiently \"normalize\" the tumor vasculature to make it more\n      efficient for oxygen delivery, thereby providing a window of opportunity for enhanced\n      sensitivity to radiation treatment. This study is to evaluate the safety, toxicity, and\n      efficacy of the addition of Endostar Continued Pumping into Vein to the standard CCRT\n      regimen in patients with unresectable stage III NSCLC."
        }, 
        "brief_title": "Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage III Non-small-Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  untreated histologic or cytologic of NSCLC verified\n\n          -  inoperable stage IIIA or IIIB NSCLC\n\n          -  measurable disease by RECIST\n\n          -  18~70 years of age\n\n          -  an ECOG PS of 0 to 1\n\n          -  absolute neutrophil count (ANC) of \u22651500/\u03bcL, hemoglobin \u226510gm/dL, platelet\n             \u2265100,000/\u03bcL\n\n          -  serum creatinine \u22641.25 times of upper limit of normal (ULN), calculated creatinine\n             clearance (CrCl) of \u226560ml/min\n\n          -  bilirubin 1.5\u00d7ULN, AST and ALT less than 2.5\u00d7ULN, alkaline phosphatase less than\n             5\u00d7ULN\n\n          -  forced vital capacity in 1 second (FEV1) higher than 0.8 L\n\n          -  CB6 is normal\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  a history of other malignant diseases\n\n          -  any contraindications for chemoradiotherapy\n\n          -  distant metastasis\n\n          -  malignant pleural and/or pericardial effusion\n\n          -  pregnant or nursing\n\n          -  preexisting bleeding diatheses or coagulopathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733589", 
            "org_study_id": "[2012]-10-24"
        }, 
        "intervention": {
            "arm_group_label": "Recombinant Human Endostatin", 
            "description": "Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.", 
            "intervention_name": "Recombinant human endostatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Endostatins"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Recombinant human endostatin", 
            "Non-small-Cell Lung Cancer", 
            "chemoradiotherapy"
        ], 
        "lastchanged_date": "December 23, 2012", 
        "location": {
            "contact": {
                "email": "gzcm@263.net", 
                "last_name": "Ming Chen, M.D.", 
                "phone": "0086-571-88122068"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310022"
                }, 
                "name": "Zhejiang Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer", 
        "overall_contact": {
            "email": "gzcm@263.net", 
            "last_name": "Ming Chen, M.D.", 
            "phone": "+86 18758875572"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "Ming Chen, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "from beginning treatment to progressive disease or the last follow-up", 
            "measure": "progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "2-year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "complete response(CR); partial response(PR); stable disease(SD); progressive disease(PD)", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "from date of beginning treatment until date of death", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "radiation-induced esophagitis; radiation-induced pneumonia", 
                "measure": "treatment related toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Zhejiang Cancer Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chinese Academy of Medical Sciences", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fudan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Beijing Cancer Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong Cancer Hospital and Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Jiangsu Cancer Institute & Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fujian Cancer Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The First People's Hospital of Lianyungang", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Zhejiang Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}